Ameriprise Financial Inc. Takes $452,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Ameriprise Financial Inc. purchased a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 53,382 shares of the specialty pharmaceutical company’s stock, valued at approximately $452,000. Ameriprise Financial Inc. owned approximately 0.11% of KalVista Pharmaceuticals at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Aquatic Capital Management LLC acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at approximately $44,000. Tower Research Capital LLC TRC raised its position in shares of KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after buying an additional 5,502 shares in the last quarter. Legal & General Group Plc raised its position in shares of KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 1,494 shares in the last quarter. Martin Worley Group acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at approximately $86,000. Finally, Algert Global LLC acquired a new position in KalVista Pharmaceuticals during the fourth quarter valued at approximately $88,000.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $13.54 on Thursday. The company has a fifty day moving average of $11.97 and a 200-day moving average of $10.54. The company has a market capitalization of $673.15 million, a PE ratio of -3.72 and a beta of 0.05. KalVista Pharmaceuticals, Inc. has a 52-week low of $7.30 and a 52-week high of $15.50.

Insider Transactions at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 2,776 shares of the business’s stock in a transaction on Monday, May 19th. The shares were sold at an average price of $11.84, for a total value of $32,867.84. Following the sale, the insider now owns 106,611 shares of the company’s stock, valued at $1,262,274.24. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Benjamin L. Palleiko sold 6,669 shares of the business’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $11.97, for a total transaction of $79,827.93. Following the completion of the sale, the chief executive officer now directly owns 287,811 shares in the company, valued at approximately $3,445,097.67. This represents a 2.26% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 15,399 shares of company stock worth $182,054. Corporate insiders own 10.50% of the company’s stock.

Analyst Ratings Changes

KALV has been the subject of several research analyst reports. Jones Trading restated a “buy” rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Needham & Company LLC restated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $24.83.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).